Dalantercept

BIOLOGICAL3 trials

Sponsors

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Gynecologic Oncology Group

Conditions

Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Transitional Cell CarcinomaEndometrial Undifferentiated Carcinoma

Phase 2

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

CompletedNCT01458392

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USASquamous Cell Carcinoma of the Head and Neck

Start: 2011-10-31End: 2015-09-30Updated: 2022-10-05

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

CompletedNCT01642082

Gynecologic Oncology GroupEndometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma +6

Start: 2012-09-30End: 2016-01-31Updated: 2018-03-13

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

CompletedNCT01720173

Gynecologic Oncology GroupRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Start: 2012-11-05End: 2019-02-19Updated: 2021-10-20

Related Papers

PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study.

Journal of Clinical Oncology2016-05-202 citations

Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.

Journal of Clinical Oncology2014-05-205 citations

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.

Journal of Clinical Oncology2014-05-204 citations